多基因与临床风险评分对心血管代谢疾病和常见癌症发病年龄及预测的影响
研究利用FinnGen生物库(n=135,300)和FINRISK研究数据,评估五种常见疾病的全基因组多基因风险评分(PRS)在临床风险预测中的附加价值。结果显示高PRS者终生风险增加21%–38%,发病提前4–9年,PRS在多种疾病中改善模型区分度和重分类。
要点
- 高PRS者终生风险较平均PRS者增加21%–38%,发病提前4–9年。
- PRS在2型糖尿病、房颤、乳腺癌和前列腺癌中改善模型区分度。
- PRS在所有疾病中改善临床阈值重分类,早发冠心病和房颤改善最大。
核心结论
- PRS在五种常见疾病的临床预测中具有附加价值。
研究设计与样本
- 利用FinnGen生物库(n=135,300)和FINRISK研究数据,评估五种疾病的全基因组PRS与临床风险评分的联合预测效果。
主要发现
- 高PRS者终生风险较平均PRS者增加21%–38%,发病提前4–9年。
- PRS在2型糖尿病、房颤、乳腺癌和前列腺癌中改善模型区分度(优于年龄和性别)。
- PRS在2型糖尿病、乳腺癌和前列腺癌中改善模型区分度(优于临床风险)。
- PRS在所有疾病中改善临床阈值重分类,早发冠心病、房颤和前列腺癌的净重分类改善最大。
临床怎么用
- PRS信息可用于分层筛查或指导生活方式和医学干预的潜力,但具体应用有待进一步研究定义。
局限性
- PRS在分层筛查或指导临床干预中的实际应用尚未明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polygenic risk scores (PRSs) have shown promise in predicting susceptibility to common diseases1-3. We estimated their added value in clinical risk prediction of five common diseases, using large-scale biobank data (FinnGen; n = 135,300) and the FINRISK study with clinical risk factors to test genome-wide PRSs for coronary heart disease, type 2 diabetes, atrial fibrillation, breast cancer and prostate cancer. We evaluated the lifetime risk at different PRS levels, and the impact on disease onset and on prediction together with clinical risk scores. Compared to having an average PRS, having a high PRS contributed 21% to 38% higher lifetime risk, and 4 to 9 years earlier disease onset. PRSs improved model discrimination over age and sex in type 2 diabetes, atrial fibrillation, breast cancer and prostate cancer, and over clinical risk in type 2 diabetes, breast cancer and prostate cancer. In all diseases, PRSs improved reclassification over clinical thresholds, with the largest net reclassification improvements for early-onset coronary heart disease, atrial fibrillation and prostate cancer. This study provides evidence for the additional value of PRSs in clinical disease prediction. The practical applications of polygenic risk information for stratified screening or for guiding lifestyle and medical interventions in the clinical setting remain to be defined in further studies.
引用
- Mars N, Koskela JT, Ripatti P, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med. 2020. PMID: 32273609. doi:10.1038/s41591-020-0800-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。